Uncategorized
Allergan, Mimetogen enter licensing agreement for tavilermide dry eye treatment
Allergan has entered into a licensing agreement with Mimetogen Pharmaceuticals to develop and commercialize tavilermide, a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease, according to an Allergan press release. Allergan will make an upfront payment of $50 million to Mimetogen and fund the phase 3 development of tavilermide (MIM-D3). Mimetogen will receive potential milestone payments and royalties based on the commercialization of the treatment, the release said.